慢性阻塞性肺疾病中的吸入性皮质类固醇：局部治疗的全身效应？
Inhaled corticosteroids in COPD: systemic effects of a local therapy?
作者信息
Antoniu Sabina A
机构信息
University of Medicine and Pharmacy 'Gr. T. Popa' Iasi, Division of Pulmonary Disease, Pulmonary Disease University Hospital, 30 Dr I Cihac Street, 700115 Iasi, Romania.
出版信息
Expert Opin Pharmacother. 2008 Dec;9(18):3271-3. doi: 10.1517/14656560802591406.
BACKGROUND
There are few data on the effects of inhaled corticosteroids on systemic inflammation in chronic obstructive pulmonary disease (COPD).
OBJECTIVE
Evaluation of the systemic anti-inflammatory effects of inhaled corticosteroids alone or in combination with long acting beta2-agonists.
METHODS
Analysis of the results of a randomized study assessing the short-term effects of inhaled fluticasone propionate, inhaled fluticasone + salmeterol and placebo on three inflammation biomarkers represented by C-reactive protein, IL-6 and surfactant protein-D.
RESULTS/CONCLUSIONS: Inhaled corticosteroids alone or in combination exhibited partial systemic anti-inflammatory effects, reducing significantly only SP-D serum levels. Further evaluation of effects of inhaled corticosteroids on various biomarkers of systemic inflammation is required in more severe stable COPD.
背景
关于吸入性糖皮质激素对慢性阻塞性肺疾病（COPD）全身炎症影响的数据较少。
目的
评估吸入性糖皮质激素单独使用或与长效β2受体激动剂联合使用的全身抗炎作用。
方法
对一项随机研究结果进行分析，该研究评估吸入丙酸氟替卡松、吸入氟替卡松+沙美特罗和安慰剂对以C反应蛋白、白细胞介素-6和表面活性蛋白-D为代表的三种炎症生物标志物的短期影响。
结果/结论：吸入性糖皮质激素单独使用或联合使用均表现出部分全身抗炎作用，仅显著降低了表面活性蛋白-D的血清水平。在更严重的稳定期COPD中，需要进一步评估吸入性糖皮质激素对全身炎症各种生物标志物的影响。
Zotero 插件